Takeda Pharmaceutical Company Limited (TAK) PEG Ratio
Potentially Undervalued
PE ratio relative to earnings growth — is the valuation justified?
0.01
PEG Ratio
0.01
Growth Rate Source
Good Data Quality5-Year EPS CAGR
Current Price
$17.38
TTM EPS
$56.53
P/E Ratio
0.31
Growth Rate
35.1%
5-Year EPS CAGR
Sector
Healthcare
Drug Manufacturers - Specialty & Generic
Calculated
8/18/2026
12:50:03 PM
Peer Comparison
Sample Size
2 peers
Industry Median PEG
0.94
25th Percentile
0.08
75th Percentile
1.80
TAK PEG (0.01) vs Industry Median (0.94): 99% discount
Symbol
Company
PEG
P/E
Growth
vs TAK
HCM
HUTCHMED (China) Limited
0.08
95.3
1225.0%
+788%
HLN
Haleon plc
1.80
15.2
8.4%
+20441%
How to Interpret PEG Ratio
PEG < 1.0 — Potentially Undervalued. The stock may be priced below its earnings growth rate, suggesting a potential buying opportunity.
PEG 1.0–2.0 — Fairly Valued. The stock price is roughly in line with its earnings growth. A PEG of 1.0 is often considered "fair value."
PEG > 2.0 — Potentially Overvalued. The stock may be priced above what its earnings growth justifies.
Limitations:PEG ratios are less reliable for financial firms (earnings driven by interest margins), companies with negative/zero earnings growth, and hypergrowth companies (>100% growth) where the ratio may appear misleadingly low. Always use PEG alongside other valuation metrics.
